Benlysta

After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad
After losing race for first to market in lupus nephritis, Aurinia taps Otsuka for voclosporin licensing pact abroad
Endpoints
Aurinia Pharmaceuticals
lupus nephritis
GSK
Otsuka
Benlysta
Flag link:
AstraZeneca lupus drug shows potential, but it may not be enough for FDA
AstraZeneca lupus drug shows potential, but it may not be enough for FDA
Biopharma Dive
AstraZeneca
lupus
anifrolumab
GSK
Benlysta
Flag link:
GlaxoSmithKline's Benlysta eyes lupus sales boost after kidney trial win
GlaxoSmithKline's Benlysta eyes lupus sales boost after kidney trial win
Fierce Pharma
GSK
Benlysta
lupus
Flag link:
GSK gets FDA nod for Benlysta to treat pediatric patients with lupus
GSK gets FDA nod for Benlysta to treat pediatric patients with lupus
Pharmaceutical Business Review
GSK
FDA
Benlysta
SLE
systemic lupus erythematosus
pediatrics
Flag link:
GSK trials Benlysta/rituximab combo for lupus
GSK trials Benlysta/rituximab combo for lupus
Pharma Times
GSK
clinical trials
Benlysta
rituximab
lupus
Flag link:
GSK gets go-ahead for new Benlysta formulation
GSK gets go-ahead for new Benlysta formulation
BioPharma Dive
GSK
Benlysta
systemic lupus erythematosus
SLE
Flag link:
Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Samsung Bioepis launches a Remicade knockoff at a 35% discount; FDA OK’s a self-administered version of Benlysta
Endpoints
Samsung Bioepis
Remicade
FDA
biosimilars
JNJ
GSK
Benlysta
lupus
Flag link:
5 Biotech Stocks With Major Catalysts in July
5 Biotech Stocks With Major Catalysts in July
Motley Fool
biotech
AcelRx
Zalviso
Alnylam
Patisiran
Dynavax
HEPLISAV-B
GSK
Benlysta
Puma Biotechnology
neratinib
Flag link:
Benlysta maker GSK drafts soccer star Boxx to get lupus patients talking
Benlysta maker GSK drafts soccer star Boxx to get lupus patients talking
Fierce Pharma
Benlysta
GSK
lupus
patients
Flag link:
GSK's lupus drug finally wins NICE backing, but only after discounts
GSK's lupus drug finally wins NICE backing, but only after discounts
BioPharma Dive
GSK
lupus
NICE
UK
Benlysta
Flag link:
AstraZeneca, GlaxoSmithKline stake rival claims on new lupus therapies
AstraZeneca, GlaxoSmithKline stake rival claims on new lupus therapies
Fierce Biotech
AstraZeneca
GSK
lupus
Benlysta
MEDI-546
Flag link:
AstraZeneca lupus drug produces positive results in trial
AstraZeneca lupus drug produces positive results in trial
Yahoo/Reuters
AstraZeneca
lupus
Benlysta
sifalimumab
Flag link:
GlaxoSmithKline Launches Phase 3 Trial for Benlysta
GlaxoSmithKline Launches Phase 3 Trial for Benlysta
Motley Fool
GSK
Benlysta
ANCA-positive vasculitis
Flag link:
10 top drug launch disasters
10 top drug launch disasters
Fierce Pharma
drug launches
Rare Disease Therapeutics
Anascorp
AstraZeneca
Brilinta
Somaxon
Silenor
Sanofi
Multaq
Savient
Krystexxa
XenoPort
Horizant
Human Genome Sciences
Benlysta
Zaltrap
Dendreon
Provenge
KV Pharmaceutical
Makena
Flag link:
Biogen Sells Benlysta Rights
Biogen Sells Benlysta Rights
Yahoo/Zacks
Biogen
Benlysta
GSK
Flag link:
3 Things to Watch With Human Genome Sciences
3 Things to Watch With Human Genome Sciences
Motley Fool
Human Genome Sciences
M&A
Benlysta
Flag link:
Lower Price of Benlysta Could Boost HGSI
Lower Price of Benlysta Could Boost HGSI
Motley Fool
Benlysta
Human Genome Sciences
GSK
lupus
Flag link:
Will Human Genome End Up Blazing A Trail For Others?
Will Human Genome End Up Blazing A Trail For Others?
Seeking Alpha
Human Genome Sciences
GSK
Eli Lilly
Benlysta
Anthera
Immunomedics
lupus
Flag link:
Human Genome jumps 12% in midday trading
Human Genome jumps 12% in midday trading
Marketwatch
Human Genome Sciences
Benlysta
Flag link:
A Bad Year for the 6,300% Miracle (Human Genome Sciences)
A Bad Year for the 6,300% Miracle (Human Genome Sciences)
Motley Fool
Human Genome Sciences
Benlysta
lupus
GSK
Flag link:

Pages